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Schizophrenia is a debilitating and chronic mental dis-
order that affects approximately 1% of the world’s pop-
ulation. Patients with schizophrenia often live alone, 
display social withdrawal, and experience difficul-
ties recognizing facial expressions (Krishnan, Keefe, 
& Kraus, 2009; Reske et al., 2009). This type of so-
cial functioning deficit (e.g., social withdrawal and so-
cial cognitive deficit) is of great concern to patients and 
their families and friends, as it directly influences how 
effectively patients with schizophrenia communicate 
and develop networks of support with those around 
them (Green et al., 2004). 
Rat social behavior under the influence of amphet-
amine (AMPH) or phencyclidine (PCP) has been used 
as a simplified model for social deficits in schizophre-
nia (Ellenbroek & Cools, 1990; Kilts, 2001; Sams-Dodd, 
1999; Tanaka et al., 2003). Despite considerable liter-
ature in this line of research, there are several impor-
tant issues that have not been adequately addressed. 
The first issue concerns the ability of AMPH to induce 
social withdrawal in rodents. While most PCP stud-
ies seem to suggest that acute and subchronic treat-
ment of PCP can reduce social interaction dose-depend-
ently (Lee, Brady, Shapiro, Dorsa, & Koenig, 2005; 
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Abstract
Although animal models based on amphetamine (AMPH) or phencyclidine (PCP) treatment have been used extensively 
to study the neurobiological and behavioral characteristics of schizophrenia, there are conflicting reports regarding 
their validity in modeling the negative symptoms and cognitive deficits of schizophrenia. The present study examined 
how acute AMPH or PCP treatment (Experiment 1) and withdrawal from repeated AMPH treatment (Experiment 2) or 
PCP treatment (Experiment 3) affects social behavior and social recognition memory in male Sprague-Dawley rats. Each 
subject was tested on two consecutive days. On the first day, the rats were tested four times (5 min/each) at 10-min in-
tervals with the same partner rat (termed “AAAA” day). One day later, the rats were tested with the previous partner in 
the first three sessions and with a new partner rat in the final session (termed “AAAB” day). The results show that acute 
AMPH treatment (1.5 mg/kg, sc) significantly reduced the time spent on social interaction, but did not affect social rec-
ognition on the first day. Acute AMPH only disrupted social recognition on the second day of drug testing. In contrast, 
acute PCP treatment (2.0 mg/kg, sc) had no effect on time spent on social interaction, but did significantly disrupt so-
cial recognition on both days. Withdrawal from repeated AMPH (3.0 mg/kg/day for 7 days, ip) or PCP (5.0 mg/kg/twice 
daily for 7 days, ip) treatment did not affect social interaction or social recognition, indicating a lack of long-term detri-
mental effect of repeated AMPH or PCP treatment. These results suggest that acute AMPH treatment at a low dose (1.5 
mg/kg) may be useful in modeling social withdrawal symptoms of schizophrenia, whereas acute PCP treatment at a sim-
ilar dose range (2.0 mg/kg) may be useful in modeling the social cognitive deficit of schizophrenia. 
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Qiao et al., 2001; Sams-Dodd, 1995, 1998a; Tanaka et 
al., 2003), this is not the case with AMPH (Young, Go-
brogge, &Wang, 2011). Some studies report that acute 
AMPH reduces social interaction (Gambill & Kornet-
sky, 1976; Schiorring & Hecht, 1979; Steinpreis, So-
kolowski, Papanikolaou, & Salamone, 1994), while 
other studies fail to show such an effect (Qiao et al., 
2001; Sams-Dodd, 1995, 1998b), and still others report 
an enhancing effect on rat social behavior (Guy & Gard-
ner, 1985). 
The second issue concerns the lack of systematic re-
search on the AMPH and PCP models for social func-
tioning deficits and their comparative validity. To our 
knowledge, there are only two studies that have exam-
ined the long-term effects of (meth)amphetamine and 
PCP sensitization on rodent social behavior. Both re-
ported that only PCP sensitization disrupted social in-
teraction in mice (Qiao et al., 2001) and rats (Lee et 
al., 2005), and that this effect could persist for at least 
28 days after the drug withdrawal (Qiao et al., 2001). 
However, most studies have focused on the acute ef-
fects of AMPH and PCP on social interaction (Sams-
Dodd, 1995; Steinpreis et al., 1994), making it diffi-
cult to tease apart the enduring and intrinsic effect 
on social behavior from the transient confusion effect 
(Qiao et al., 2001).With regards to the relative valid-
ity, some suggest that the PCP model is better, because 
it induces thought disorders and negative symptoms, 
such as social withdrawal in rodents (Qiao et al., 2001; 
Sams-Dodd, 1998a, 1998b). For example, Qiao et al. 
(2001) found that withdrawal from repeated PCP treat-
ment, but not from (meth)amphetamine, reduced social 
interaction in mice. However, this finding is at odds 
with some clinical (Srisurapanont et al., 2003) and pre-
clinical observations (Ellenbroek & Cools, 2000). There 
are still other researchers suggesting that the AMPH 
model is better because only the AMPH sensitization 
withdrawal model in animals is capable of reproduc-
ing information-processing deficits that are impaired 
in schizophrenia, as measured in prepulse inhibition 
(PPI), latent inhibition and attentional set shifting 
tasks (Fletcher, Tenn, Rizos, Lovic, & Kapur, 2005; 
Tenn, Kapur, & Fletcher, 2005). Studies that directly 
compare the acute and subchronic effects of AMPH and 
PCP in social behavior models encompassing a social 
cognition component may help address this issue. 
In the present study, we attempted to address 
these issues using a repeated social interaction test-
ing paradigm. We examined and compared the abil-
ity of acute and repeated AMPH and PCP treatment 
in reproducing social withdrawal and social recogni-
tion (a type of working memory) deficit, one of seven 
primary cognitive domains that are affected in schizo-
phrenia (Floresco, Geyer, Gold, & Grace, 2005; Green 
et al., 2004). In this task, a subject rat was given mul-
tiple encounters with a partner rat (weight-matched) 
in a new testing cage. The social memory of rats is evi-
denced by the findings that a normal rat will decrease 
its time investigating the same testing partner after 
a waiting period (approximately 10 min) and will in-
crease its time on investigation if a novel partner is in-
troduced (Akers et al., 2006; Holloway & Thor, 1988; 
Prediger, Batista, Miyoshi, & Takahashi, 2004). There-
fore, this paradigm allowed us to examine not only the 
effects of AMPH and PCP on social interaction, but also 
their impacts on social cognition (social recognition) in 
a natural behavior context (Akers et al., 2006; Hollo-
way & Thor, 1988; Prediger et al., 2004). 
Methods 
Animals 
Male Sprague-Dawley rats (226–250 g on arrival; 
Charles River, Portage, MI, USA) were housed two per 
cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent poly-
carbonate cages with food and tap water available ad 
lib. The subjects were maintained on a day–night cy-
cle of 12 hr : 12 hr (light on between 6:30 a.m. and 6:30 
p.m.). The room temperature was maintained at 22 ± 
1°C and the humidity was controlled at 45–60%. The 
subjects were housed at the animal facility for at least 
7 days before they were used in the behavioral testing. 
This animal use protocol was approved by the local In-
stitutional Animal Care and Use Committee. 
Drugs 
Dextroamphetamine sulfate was purchased from 
Sigma-RBI and phencyclidine hydrochloride was gift 
from the NIDA Chemical Synthesis and Drug Supply 
Program. They were dissolved in 0.9% saline. All injec-
tions were administered at a volume of 1 ml/kg. 
Experiment 1: Effect of acute AMPH and PCP treat-
ment on social interaction and social recognition 
Prior to testing, 24 experimental rats were randomly 
assigned to one of three groups: those treated with sa-
line (SAL, n = 8), AMPH (n = 8), or PCP (n = 8). They 
were termed “subjects.” Another 12 rats were simply 
used as partners for the social behavior tests (termed 
“partners”). All rats were first handled for 2 days. On 
each handling day, the subject rats in the SAL, AMPH, 
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and PCP groups were handled for approximately 2 
min each, given subcutaneous injections of saline, and 
placed into large transparent observation cages (51 cm 
× 38.1 cm × 19 cm) with wood shavings for bedding 
for 5 min. The rats in the partner group were handled 
on the same 2 days but did not receive any injections. 
They were housed in separate cages from the experi-
mental rats. 
Following handling, each subject rat received two 
consecutive days of testing. On each test day, the sub-
ject first received a single subcutaneous injections of sa-
line, AMPH 1.5 mg/kg, or PCP 2.0 mg/kg and was im-
mediately placed into an observation cage. Ten minutes 
later, the first partner was introduced to the subject, 
and social interaction was videotaped for 5 min, after 
which the partner was removed and returned to a sep-
arate holding cage. This procedure was repeated three 
additional times at 10-min intervals, thereby giving ev-
ery subject four 5-min test sessions per day. To distin-
guish between the partner rats and the subject rats, 
the former were tagged by drawing stripes on their 
back with a black marker. On Day 1, each subject was 
tested with the same partner in all four sessions. This 
day was termed the “AAAA” day, denoting that the four 
5-min tests used the same “A” partner. On Day 2, 10 
min after saline, AMPH 1.5 mg/kg, or PCP 2.0 mg/kg 
injection, each subject was again tested with the pre-
vious partner (“A”) in the first three sessions and with 
a new partner (“B”) in the final session. This day was 
termed the “AAAB” day (see Figure 1 for the general 
experimental procedure). 
The amount of time (in seconds, 300 s max) that a 
subject rat engaged in social behaviors, including sniff-
ing (whole body and anogenital area), climbing over 
and crawling underneath the partner, grooming, box-
ing, and closely following its partner, was later scored 
by two trained raters using JWatcher behavioral cod-
ing software (http://www.jwatcher.ucla.edu/). Please 
note that any social contact initiated by the partner 
was not counted to ensure an accurate recording of only 
drug-induced disruption of social behavior. The results 
from each rater were compared and averaged if the dif-
ferences were less than 20 s. Otherwise, the disputed 
test sessions were recoded by the two raters and by an 
additional trained rater. The subsequent results were 
compared and the two closest data points were aver-
aged. Because many of the individual social behaviors 
often occurred simultaneously and could not be easily 
distinguished, we totaled the time spent on social in-
teraction and used it for data analysis. Social memory 
was indexed by the across-session, progressive decline 
in the time spent on social interaction on the AAAA 
day, and the initial decline in the first three sessions 
and recovery of the interaction time in the last session 
on the AAAB day. Thus, to examine the effects of acute 
AMPH and PCP on social recognition memory, we used 
the following formulas to calculate the social memory 
indices for each subject: 
Social memory on AAAA day 
   = [(session 4 – session 1) ÷ session 1] × 100% 
Social memory on AAAB day 
   = [(session 3 – session 1) ÷ session 1] × 100% 
The above formulas calculated the percentage change 
in social interaction time from the first session to the 
fourth or third session. The AMPH and PCP doses were 
chosen because they are commonly used in the liter-
ature (Arnt, 1995; Gleason & Shannon, 1997; Mintz, 
Russig, Lacroix, & Feldon, 2005; Natesan, Reckless, 
Nobrega, Fletcher, & Kapur, 2006; Sams-Dodd, 1998b; 
Sills, Greenshaw, Baker, & Fletcher, 2000; Steinpreis 
et al., 1994; Sun, Hu, & Li, 2009). All social behavior 
tests were run during the light cycle at approximately 
the same time on both days. 
Experiment 2: Effect of withdrawal from repeated 
AMPH treatment on social interaction and social 
recognition 
Twenty-four rats were pseudo-randomly assigned to 
one of three groups (n = 8/group; SAL, AMPH, or con-
trol) so that the rats housed in the same cages received 
the same drug treatment. After 1 week of habituation 
and 2 days of handling (1 min/rat/day), the rats in the 
AMPH and SAL groups received intraperitoneal injec-
tions of 3.0 mg/kg AMPH or saline (0.9%, 1 ml/kg), re-
spectively, once daily for seven consecutive days. As in 
Experiment 1, the rats in the partner group were han-
dled but did not receive any injections. This AMPH 
treatment regimen was chosen based on previous 
Figure 1. A schematic depiction of the 
experimental procedure in Experiment 1. 
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reports that it produces robust locomotor sensitization 
and enhances behavioral responses to reward (Avena 
& Hoebel, 2003; Wyvell & Berridge, 2001). The social 
behavior tests started 1 week after the last drug injec-
tion. The basic procedure was identical to that of Ex-
periment 1. The rats were first tested with the same 
partner rat in all four sessions on the AAAA day. One 
day later, the subject rat was tested with the previous 
partner in the first three sessions and with a new part-
ner in the final session on the AAAB day. 
Experiment 3: Effect of withdrawal from repeated 
PCP treatment on social interaction and social 
recognition 
In Experiment 3, 24 rats were pseudo-randomly as-
signed to one of three groups (n = 8/group; SAL, PCP, or 
control). The rats in the PCP and SAL groups received 
twice-daily injections of 5.0 mg/kg PCP or 0.9% saline 
(1 ml/kg) at approximately 8:00 a.m. and 6:00 p.m. for 
seven consecutive days prior to social behavior test-
ing. This PCP treatment regimen is shown to induce a 
decrease in prefrontal dopaminergic utilization, aug-
mented motor activity, and various cognitive deficits 
(Dunn & Killcross, 2006; Jentsch & Taylor, 2001; Jen-
tsch, Tran, Le, Youngren, & Roth, 1997; Rodefer, Mur-
phy, & Baxter, 2005). Similar to Experiment 2, social 
behavior tests started 1 week after the last drug injec-
tion, and each rat was tested on two consecutive days 
(i.e., AAAA and AAAB day).To monitor the progress 
of behavioral sensitization with repeated PCP treat-
ment, both PCP and saline-treated rats were tested 
in a motor activity monitoring system over the treat-
ment period: (1) the day before the first drug injection; 
(2) immediately after the first injection; (3) immedi-
ately after the seventh injection and (4) immediately 
after the 14th injection for 60 min. The testing boxes 
were 48.3 cm × 26.7 cm × 20.3 cm transparent polycar-
bonate cages, each equipped with a row of six photo-
cell beams (7.8 cm between two adjacent photo beams) 
placed 3.2 cm above the floor of the cage. A computer 
detected the disruption of the photocell beams and re-
corded the number of beam breaks. 
Statistical analysis 
To identify the treatment effects, the total time spent 
on social interaction on each test day (the sum of four 
sessions) and measurements of social memory were an-
alyzed using a one-way analysis of variance (ANOVA) 
with the treatment as the between-subjects factor, fol-
lowed by a post hoc least significant difference (LSD) 
test. To identify changes across sessions, the data were 
analyzed using repeated-measures ANOVA with the 
treatment as the between-subjects factor (“Treatment”: 
AMPH, PCP, or SAL) and the test sessions (“Session”: 
AAAA or AAAB) as the within-subjects factor, followed 
by a post hoc LSD test. Any PCP-induced change in 
motor activity was analyzed using repeated-measures 
ANOVA. A conventional two-tailed level of significance 
at the 5% level was required for all tests. 
Results 
Experiment 1: Effect of acute AMPH and PCP 
treatment on social interaction and social 
recognition 
Acute AMPH treatment, but not PCP reduced social 
interaction 
Figure 2 shows the total time spent on social inter-
action on each test day (a sum of the four sessions 
from the AAAA and AAAB test days) for each treat-
ment group. It appears that acute AMPH (1.5 mg/kg, 
sc) treatment reduced social interaction, particularly 
on the AAAB day. In contrast, acute PCP (2.0 mg/kg, 
sc) treatment had little effect on this measure. One-
way ANOVA confirmed this observation. On the AAAA 
day, there was a significant effect of “Treatment,” F(2, 
23) = 14.629, p < .001. Post hoc tests indicate that the 
AMPH group was significantly different from the SAL 
group, p < .001, whereas the PCP group was not, p = 
.618. On the AAAB day, the treatment effect was not 
statistically significant, F(2, 23) = 2.495, p = .107, also 
the AMPH group was only marginally different from 
the SAL group, p = .052, suggesting that the last ses-
sion with a novel partner (i.e., the “B” session in the 
“AAAB”) on that day may have attenuated the disrup-
tive effect of AMPH to some extent. 
To gain a more detailed understanding of the acute 
effect of AMPH and PCP treatment on social behav-
ior, we depict social interaction time across the four 
sessions on the two test days in Figure 3. Once again, 
the disruptive effect of AMPH was apparent (Figure 
3A). For the AAAA day, repeated-measures ANOVA 
revealed a significant effect of “Session,” F(3, 63) = 
27.845, p < .001, a significant effect of “Treatment,” 
F(2, 21) = 14.629, p < .001, and “Session” × “Treat-
ment,” F(6, 63) = 4.023, p = .002, interaction. Post hoc 
tests showed that, once again, AMPH-treated rats 
spent less time on social interaction than did the SAL 
rats, p < .001. No such difference was seen between 
the PCP-treated and the SAL rats, p = .618. One-way 
ANOVA followed by LSD post hoc tests at each test 
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Figure 2. Effects of acute 
amphetamine (AMPH; 1.5 mg/
kg, sc) or phencyclidine (PCP; 
2.0 mg/kg, sc) administration 
versus saline (SAL) treatment on 
social interaction in rats. Social 
interaction tests were conducted 
on 2 days for each rat, the first day 
of which used the same partner 
across the four 5-min sessions 
separated by a 10-min interval 
(AAAA), and the second of which 
used the same partner in the first 
three sessions, and an unfamiliar 
partner in the fourth session 
(AAAB). Data are expressed as 
mean ± SEM total social behavior 
time summed from four sessions. 
*p < .05 versus SAL.  
Figure 3. Effects of acute amphetamine 
(AMPH; 1.5 mg/kg, sc) or phencyclidine 
(PCP; 2.0 mg/kg, sc) administration 
versus saline (SAL) treatment on social 
interaction in rats across the four test 
sessions on the AAAA and AAAB days. 
Data are expressed as mean ± SEM 
social interaction time recorded in each 
session. *p < .05 versus SAL.  
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session showed that the AMPH-treated rats differed 
significantly from the SAL rats on the first, second, and 
fourth session, all p < .028 for each, whereas the PCP-
treated rats differed from the SAL rats on the first ses-
sion, p = .019, and the last session, p = .026. Inspec-
tion of Figure 3B suggests that the PCP rats actually 
spent more time on social interaction on the last test-
ing session. Overall, acute treatment of AMPH, but not 
PCP, produced a significant detrimental effect on so-
cial interaction. 
For the AAAB day, repeated-measures ANOVA 
revealed a significant effect of “Session,” F(3, 63) = 
32.817, p < .001, and “Session” × “Treatment” inter-
action, F(6, 63) = 5.343, p < .001, but no main effect 
of “Treatment,” F(2, 21) = 2.495, p = .107. Post hoc 
tests showed that the AMPH-treated rats showed re-
duced social interaction only on the first session, p = 
.004 versus SAL, whereas the PHP-treated rats showed 
increased social interaction on the third session, p = 
.018 versus SAL. Once again, only the acute treatment 
of AMPH, but not PCP, disrupted social interaction. 
Acute PCP treatment disrupted social memory on both 
testing days, whereas acute AMPH only disrupted social 
memory on the second day of testing 
Using the social memory calculation formulas men-
tioned in the Methods section, we calculated the per-
centage change in social interaction time from the first 
session to the fourth or third session. The results are 
depicted in Figure 4. One-way ANOVA showed a sig-
nificant main effect of “Treatment” for both the AAAA 
day, F(2, 23) = 7.830, p = .003, and the AAAB day, F(2, 
23) = 4.58; p = .022. Post hoc tests revealed that the 
PCP-treated rats showed an impaired social memory on 
both days in comparison to the SAL rats, p = .004 and 
p = .032, respectively, whereas the AMPH-treated rats 
only showed an impaired social memory on the second 
Figure 4. Effects of acute amphetamine 
(AMPH; 1.5 mg/kg, sc) or phencyclidine 
(PCP; 2.0 mg/kg, sc) administration 
versus saline (SAL) treatment on social 
recognition memory in rats measured 
on (A) day AAAA and (B) day AAAB. The 
social memory index was calculated as the 
percentage change in social interaction 
time from the first session to the fourth 
(for day AAAA) or the third session (for 
day AAAB). *p < .05 versus SAL.  
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day of testing (i.e., AAAB day, p = .009), but not on the 
first day (i.e., AAAA day, p = .733). 
Another measure of social recognition memory on 
the AAAB day was the recovery of social interaction 
from the third session to the fourth session due to the 
introduction of a novel partner. This effect was most 
conspicuous in the AMPH and SAL groups, and less 
so in the PCP group (Figure 3). Further analyses con-
firmed this observation. Repeated-measures ANOVAs 
examining the change from the third to the fourth ses-
sion indicated a significant “Session” × “Treatment” 
interaction between the AMPH and SAL groups, F(1, 
14) = 5.839, p = .030, and between the PCP and SAL 
groups, F(1, 14) = 11.971, p = .004, suggesting that 
both AMPH and PCP disrupted this measure of social 
memory, with PCP showing a more severe disruption 
than AMPH. 
Experiment 2: Effect of withdrawal from repeated 
AMPH treatment on social interaction and social 
recognition 
Figure 5 shows the social interaction (in seconds) of 
the rats that were previously treated with AMPH (3.0 
mg/kg, ip) or saline for 7 days on each of the two test 
days. It appears that 1-week withdrawal from repeated 
AMPH treatment did not affect social interaction or 
social memory. Both groups showed a progressive de-
cline in the amount of time spent on social interaction 
across the four test sessions on the AAAA day, as re-
flected by a highly significant main effect of “Session,” 
F(3, 42) = 9.737, p < .001. However, there was no sig-
nificant main effect of “Treatment,” F(1, 14) = 0.397, p 
= .539, or “Treatment” × “Session” interaction, F(3, 42) 
= 1.201, p = .321, suggesting that prior AMPH treat-
ment did not significantly impact social interaction and 
social memory. 
This lack of an effect of AMPH withdrawal on social 
interaction and social memory was also seen on the 
AAAB day. Both the AMPH and the SAL rats showed 
a progressive decline in the social interaction scores 
over the first three sessions and a rebound at the fourth 
session. There was a highly significant main effect of 
“Session,” F(3, 42) = 7.074, p = .001, but no significant 
main effect of “Treatment,” F(1, 14) = 0.185, p = .673, 
or “Treatment” × “Session” interaction, F(3, 42) = 0.249, 
p = .861. Inspection of Figure 5 shows that the intro-
duction of a new partner at the fourth session reversed 
the declining trend in social interaction across the first 
three sessions in both groups equally. 
Experiment 3: Effect of withdrawal from repeated 
PCP treatment on social interaction and social 
recognition 
Figure 6A depicts the social interaction (in seconds) 
of the rats that were previously treated with PCP (5.0 
mg/kg, twice daily, ip) or SAL for 7 days on each of 
the two test days. Similar to the data patterns seen in 
Experiment 2, 1-week withdrawal from repeated PCP 
treatment did not impair social interaction and so-
cial memory. Both the PCP and SAL groups decreased 
their social interaction progressively on the AAAA day. 
This observation was confirmed by statistical analyses 
showing a main effect of “Session,” F(3, 42) = 24.723, 
p < .001, but no main effect of “Treatment,” F(1, 14) = 
0.051, p = .824, or “Treatment” × “Session” interaction, 
F(3, 42) = 0.161, p = .922. 
Figure 5. Effects of withdrawal from 
amphetamine (AMPH) sensitization 
(3.0 mg/ kg, ip, daily for 7 days) 
versus saline (SAL) treatment on 
social interaction and social memory 
in rats. Social interaction tests were 
conducted on two consecutive days 
(AAAA followed by AAAB). Data are 
expressed as mean ± SEM social 
interaction time recorded in each 
session. 
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On the AAAB day, there was a clear initial decline 
and later rebound data pattern in the time spent on so-
cial interaction in both the PCP and SAL groups. Again, 
no PCP-withdrawal effect was detected, as reflected by a 
lack of significant effect of “Treatment,” F(1, 14) = 0.066, 
p = .801, and “Treatment” × “Session” interaction, F(3, 
42) = 0.953, p = .424. However, there was a significant 
main effect of “Session,” F(3, 42) = 8.207, p < .001, sug-
gesting that the introduction of a new partner at the 
fourth session completely reversed the social interac-
tion decline in both groups. This further demonstrates 
that the rats were able to recognize their partners and 
to discriminate the old from the new. 
In this experiment, we also measured motor activ-
ities during the induction phase of PCP sensitization. 
As can be seen in Figure 6B, repeated PCP injections 
significantly enhanced motor activity throughout this 
period. There was a significant effect of treatment, F(1, 
14) = 114.964, p < .001, a significant effect of tests, F(3, 
42) = 9.654, p < .001, and treatment × tests interaction, 
F(3, 42) = 8.957, p < .001, suggesting that repeated PCP 
treatment at this dose did induce a behavioral sensi-
tization effect. 
Discussion 
Impaired social interaction (e.g., social withdrawal) 
and social cognition are the core symptoms of schizo-
phrenia and have been modeled extensively using rat 
Figure 6. (A) Effects of withdrawal from 
phencyclidine (PCP) sensitization (5 mg/
kg, ip, twice daily for 7 days) versus saline 
(SAL) treatment on social interaction and 
social memory in rats. Social interaction 
data are expressed as mean ± SEM time 
across the sessions. (B). PCP-induced 
hyperlocomotion (sensitization) during 
the induction phase on the day before 
the first drug injection, immediately after 
the first, seventh and 14th injection, are 
expressed as mean + SEM motor activity 
counts. *p < .05 versus SAL.  
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social interaction paradigms (Green et al., 2004). In 
this study, we demonstrated that acute AMPH treat-
ment caused a significant reduction in the amount of 
time spent on social interaction, but did not affect so-
cial recognition until the second drug test day. In con-
trast, acute PCP treatment had no effect on social 
interaction, but did significantly disrupt social recog-
nition. Withdrawal from repeated AMPH or PCP treat-
ment did not affect social interaction or social recogni-
tion, indicating a lack of long-term detrimental effect 
of repeated AMPH or PCP treatment. These results 
suggest that acute AMPH treatment may be useful 
in modeling social withdrawal-like behavior, whereas 
acute PCP treatment may be useful in modeling the so-
cial cognitive deficit of schizophrenia. Both withdrawal 
models (AMPH and PCP) based on the current treat-
ment regimens are ineffective in providing a reliable 
model of social withdrawal and social cognitive deficits 
in schizophrenia. 
In Experiment 1, we showed that a single injection 
of AMPH at 1.5 mg/kg was able to substantially reduce 
the time spent on social interaction. Because we only 
coded the interaction initiated by the AMPH-treated 
rats, this finding indicates that acute AMPH induced 
a social withdrawal-like behavior. This result is consis-
tent with many reports in the literature showing that 
acute AMPH reduces social interaction in animals (El-
linwood, Sudilovsky, & Nelson, 1973; Gambill & Kor-
netsky, 1976; Schiorring & Hecht, 1979; Steinpreis et 
al., 1994) and causes rats to actively withdraw from so-
cial contact (Kuppinger, Harrington, Kaczmerek, Pa-
nos, & Steinpreis, 1996). However, this result does not 
agree with other studies showing that acute and con-
tinuous infusion of AMPH failed to reduce social activ-
ity in rats (Sams-Dodd, 1995, 1998a). This discrepancy 
is likely due to a variety of methodological differences 
between the studies, such as differences in rat strain 
(e.g., Wistar vs. Sprague-Dawley), AMPH dosage (e.g., 
1.5 mg/kg vs. 0.125–4.0 mg/ kg), injection-testing inter-
val (e.g., 45 min vs. 10 min), testing duration (e.g., 5 
min vs. 10 min or 30 min), and testing conditions (e.g., 
low-light vs. regular light), etc. Thus, there may likely 
exist boundary conditions in which AMPH achieves its 
disruptive effect on social interaction, and figuring out 
these conditions in future studies may help us to under-
stand how drug–environment interaction determines 
the behavioral effects of AMPH (Anagnostaras & Rob-
inson, 1996). 
Although it is often reported that acute or sub-
chronic treatment of PCP dose-dependently reduces so-
cial interaction, and this reduction is dissociable from 
the other effects of PCP, such as stereotypy, hyperloco-
motion, and ataxia (Lee et al., 2005; Sams-Dodd, 1995, 
1999), there are other reports in the literature that 
have failed to find such a disruptive effect, particularly 
at the dose used in the present study. For example, 
Steinpreis and her colleagues found that PCP at 1.0– 
2.0 mg/kg was generally ineffective in disrupting rat so-
cial behavior, and a reliable disruptive effect started to 
appear when PCP reached 4.0 mg/kg (Steinpreis et al., 
1994; Steinpreis & Salamone, 1993). Recently, Mintz 
et al. (2005) used a more sophisticated behavioral anal-
ysis technique and examined the disruptive effect of 
PCP treatment on social interaction in an open field-
test environment. They differentiated social interaction 
occurring in the home-base state and in the exploration 
state. Their results also showed that PCP at 2.0 mg/kg 
had no effect on total social interaction (measured as 
“social proximity,” defined as the amount of time that 
rats are less than 20 cm apart), and no effect on social 
interaction in the home base during the first 10 min of 
testing. Similarly, Audet, Goulet, and Dore (2009) also 
failed to find any acute effect of PCP treatment on the 
total time spent in social interaction and the time spent 
on affiliative contacts (e.g., approach, sniffing, follow-
ing). Thus, like AMPH, the socially disruptive effect of 
PCP is most likely dependent on the drug doses and 
testing conditions. The notion that only PCP, and not 
AMPH, can mimic social withdrawal should be aban-
doned in favor of the idea that both psychotomimetic 
drugs can induce social withdrawal under the appro-
priate conditions. Thus, efforts should be directed to-
wards identifying the conditions in which AMPH and 
PCP disrupt or do not disrupt social behavior, and on 
what aspects of social behavior. 
In group-living mammals such as rodents, the abil-
ity to recognize conspecifics (social memory) is criti-
cally important for reproduction, territorial defense, 
and the establishment of dominance hierarchies (Fer-
guson, Young, & Insel, 2002). In the laboratory, so-
cial memory is often assessed reliably by measuring 
the reduction in investigation of a familiar partner rel-
ative to novel conspecifics (Thor & Holloway, 1982). 
In the present study, we used two testing regimens 
(AAAA and AAAB) and obtained two different mea-
sures of social memory: an across-session, progressive 
decline in the time spent on social interaction on the 
AAAA day, and a recovery of the interaction time in 
the last session on the AAAB day. Our results indi-
cate that acute PCP treatment impaired social recog-
nition, despite its lack of effect on social interaction 
per se. Acute AMPH treatment on the second test day 
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(i.e., AAAB) also showed a disruption of social recogni-
tion. To the best of our knowledge, this is the first re-
port that shows the memory impairment effect of PCP 
(to a lesser extent, AMPH) in a natural social context, 
although PCP is known to disrupt learning and (work-
ing) memory in laboratory-based artificial tasks (An-
dersen & Pouzet, 2004; Dunn & Killcross, 2006; Jen-
tsch & Anzivino, 2004; Mandillo, Rinaldi, Oliverio, & 
Mele, 2003). These findings are also consistent with a 
clinical observation showing that PCP psychosis nor-
mally occurs 20–40 min following single or repeated ad-
ministration (Davies & Beech, 1960), whereas AMPH 
psychosis usually occurs after a prolonged period of ex-
posure (Bell, 1965; Ellinwood et al., 1973), confirming 
the clinical relevance of this preclinical approach. 
The social memory disruptive effect of acute PCP is 
significant because it shows that an acute PCP treat-
ment model may be a useful model of the social cogni-
tive deficit of schizophrenia. In recent years, cognitive 
deficits associated with schizophrenia have received 
much attention (Green et al., 2004), of which social cog-
nition is one (Floresco et al., 2005; Green et al., 2004). 
So far, much work has focused on attention, working 
memory, and executive functioning (Jentsch et al., 
1997; Martinez, Oostwegel, Geyer, Ellison, & Swerd-
low, 2000; Schroeder, Schroeder, Darius, Grecksch, & 
Sabel, 1998; Tenn, Fletcher, & Kapur, 2003). There is 
still a glaring lack of naturalistic animal models of so-
cial cognitive deficits that cuts across mammalian spe-
cies. The present study filled this critical gap by dem-
onstrating that: (a) it is possible to develop an animal 
model based on PCP treatment to mimic the social cog-
nitive deficit of schizophrenia; and (b) it is possible to 
examine other cognitive deficits, such as attention and 
working memory in a natural context. If future work 
confirms this effect of PCP, we could investigate the un-
derlying neural and neurochemical mechanisms. 
Repeated administration of AMPH and PCP in-
duces behavioral and neurochemical changes that 
persist beyond the termination of drug treatment. In 
the present study, we failed to observe any long-term 
disruptive effect of AMPH and PCP withdrawal on 
rat social interaction or social cognition deficit. This 
lack of effect could not be attributed to the insensitiv-
ity of our social behavior testing procedure, because 
the rats were tested in a total of eight sessions in this 
paradigm and clearly adjusted the amount of time 
spent on social interaction when a novel partner was 
introduced after a familiar one. The lack of effect of 
AMPH withdrawal is consistent with what has been 
reported in the literature (Sams-Dodd, 1998a, 1998b). 
In contrast, the lack of effect of PCP withdrawal is 
inconsistent with others (Lee et al., 2005; Qiao et al., 
2001; Sams-Dodd, 1995, 1999). However, a recent mice 
study using the same PCP treatment and withdrawal 
regimen as used in the present study also failed to de-
tect a severe social impairment effect with repeated 
PCP, and called for further analysis of the potential 
utility of subchronic PCP treatment for modeling the 
social withdrawal component of schizophrenia (Brig-
man, Ihne, Saksida, Bussey, & Holmes, 2009). As 
in the case of AMPH studies, differences in testing 
schedules and PCP treatment regimens may contrib-
ute to the discrepancies among various PCP studies. 
As rightly pointed out by Fletcher et al. (2005), “the 
precise parameters of PCP treatment may be critically 
important in determining whether repeated treatment 
with PCP has long-term effects on cognition and on 
dopamine function” (p. 197). 
The negative result from the PCP-treated rats on 
social recognition memory was unexpected, given that 
the same sensitization regimen (i.e., twice-daily injec-
tions of 5 mg/kg PCP for 7 days) has been shown to im-
pair animal performance in a spatial working memory 
task, reduce basal dopamine utilization in the prefron-
tal cortex, and disrupt the animal’s ability to flexibly 
adjust behavioral responses based on new or changed 
contingencies between stimulus and reward (Dunn & 
Killcross, 2006; Jentsch et al., 1997; Jentsch & Tay-
lor, 2001; Rodefer et al., 2005). However, Stefani and 
Moghaddam (2002) also reported that rats treated with 
PCP or AMPH according to treatment regimens simi-
lar to ours did not show a lasting, significant working 
memory impairment in a discrete, paired-trials delayed 
alternation task. Egerton et al. (2008) also failed to ob-
serve any disruption of social behavior in rats repeat-
edly treated with PCP via injections or mini-pumps. 
Our study highlights a need to employ a diverse group 
of behavioral tasks to cross-validate animal models of 
the cognitive dysfunctions of schizophrenia. It is pos-
sible that PCP is less potent in disrupting cognitive 
function in an ethologically relevant behavioral con-
text, such as a socially interactive paradigm, than in 
artificially created behavioral paradigms. 
In conclusion, the present study demonstrated that 
social withdrawal is better induced by acute AMPH ad-
ministration, and a social cognitive deficit is better in-
duced by acute PCP administration. Withdrawals from 
repeated AMPH and PCP treatment are limited in the 
ability to induce social withdrawal and social cognitive 
deficits. Thus, in the development of animal models of 
schizophrenia, we suggest that acute AMPH treatment 
may be useful in modeling social withdrawal-like be-
havior, whereas acute PCP treatment may be useful 
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in modeling the social memory deficit of schizophrenia. 
Both AMPH and PCP sensitization withdrawal models 
based on the regimens used in the present study and 
testing parameters are less likely to provide a reliable 
model of social withdrawal and social cognitive deficits 
in schizophrenia.
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